This trial is evaluating whether Epigallocatechin gallate (EGCG) will improve 1 primary outcome in patients with Cancer of Colon. Measurement will happen over the course of 1 year.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. Epigallocatechin Gallate (EGCG) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.
About 10% of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) is related to hereditary factors. More than half of colorectal cancers are related to unhealthy lifestyle. Cigarette smoking is the most important risk factor for colorectal cancer, especially for those who develop cancer before 50 years of age.
Symptoms of cancer of colon may first present as a general feeling of not being well. The most common symptoms include change in weight or shape, blood in stool (not always blood), diarrhea, feeling tired, an unexplained fall in temperature, unexplained fatigue or a cough. In children a lump around the mouth, lips or a protruding tongue may occur as the disease progresses. As the cancer progresses, a general feeling of not being well develops with the symptoms becoming more urgent. In time, a constant feeling of fatigue is noted with the cancer affecting the lining of the bowel. Other early signs may be unexplained blood in the sputum, itchiness of the hands or feet, diarrhea, anaemia, blood in the urine and back pain.
Even if some early lesions are detected early, most of the polyps in stage I will be stable when the patient is in later life. Even if early lesions or those with high-grade dysplasia are found in later life, early and aggressive treatment is indicated.
Only two medications, folic acid and vitamin B12, have been found to be effective in reducing the risk of colorectal cancer in women who have had abnormal results from screening and/or a colonoscopy. Colonoscopy and genetic screening may help women who have not yet developed colorectal cancer choose the best personalized treatment options.
A cancer of colon is a type of colon cancer. Colon cancer is an invasive cancer that most commonly affects colon tissue. When it invades the blood vessels and lymphatic ducts, it is called a 'lymphatic invasion' cancer. The most common type of colon cancer is adenocarcinoma. There are two types of adenocarcinomas: 'distal' (or right colon cancer) and 'proximal' cancers. If you are looking to join a colon cancer clinical trial, [Power(https://www.power.org/clinical-trials/medical-condition/colon-cancer) can help you search recent trials by condition, treatment or location]].
The estimates reported in this study of persons diagnosed with cancer of colon differ substantially from a nationwide population-based study. It is unclear whether the difference is a real effect of the survey design or a reflection of the different demographic characteristics of those eligible for the population-based survey. Given the differences, caution may be prudent in applying population estimates of relative cancer risk estimates to patients treated in specialty practices.
EGCG has been the subject of extensive research and clinical development since its discovery by Professor Robert O'Grady at the University of Florida in the 1960s.
Although the sample was too small to definitively prove this, and the lack of randomisation of the treatment groups, the results are very intriguing. EGCG may be an anti-cancer agent, with better results for colon cancer and possibly worse results for lung cancer of all kinds and esophageal cancer. The use of EGCG could be very helpful in preventing and treating a number of types of cancer but as of the end of October the manufacturer has not made the results available to the scientific community.
Adenomatous polyps and colonic neoplasia are equally common in patients with chronic [ulcerative colitis](https://www.withpower.com/clinical-trials/ulcerative-colitis). Thus a colonic carcinoma has to be ruled out if a patient or a colonoscopist is found to have ulcerative colitis. Histologically it is difficult to discriminate adenomatous colitis from colonic neoplasia, so careful examination of the colonic mucosa is essential. In addition neoplasia can also occur in the colon in Crohn disease (3-4%), particularly where it has existed for decades (>10 years, for example).
Results from a recent clinical trial suggest that the reported high prevalence of EGCG use in cancer prevention studies may have been influenced by the existence of bias in study design and/or data extraction, rather than EGCG as a treatment by itself.
Even the most aggressive therapies may not be cure for colon cancer. The survival rate in our series is similar to that in the literature in the Western society. In our series, there were no differences in survival according to type of surgery and the stage of disease.
For most patients, cancer of colon should be considered as a serious illness. Patients are not well aware of the seriousness of this disease or the treatment options, which are very different. The role of the medical oncologist in this treatment requires clarification and education of the patients, especially the impact of possible cure of the disease.